Spondyloarthropathies News

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

To avoid perpetuating misinformation regarding rheumatic diseases, rheumatologists should ensure they are aware of the available evidence – or lack thereof – for some of the popular myths patient hold about their disease, noted a speaker at the EULAR 2021 Congress.

Patients who received rheumatology care from nurse practitioners or physician assistants rated their overall experience similarly to those who saw a rheumatologist, according to survey data published in Arthritis Care & Research.

Routine care for inflammatory arthritis should include self-management strategies that feature problem-solving, goal-setting and, if possible, cognitive behavioral therapy, according to new EULAR recommendations.

Air pollution is a predictor of poor response to biological treatment in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a poster session at the EULAR 2021 Congress.

Most patients with active, radiographic axial spondyloarthritis who receive ixekizumab for 2 years show no radiographic disease progression, with low mean progression overall, according to a poster presentation at the EULAR 2021 Congress.

Tofacitinib 2 mg twice daily demonstrated “significantly greater” efficacy than placebo in adults with ankylosing spondylitis, according to researchers writing in the Annals of the Rheumatic Diseases.

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit.

European patients with axial spondyloarthritis wait an average of more than 7 years between the first appearance of symptoms and receiving a diagnosis, according to data published in Rheumatology.